Compare SVRA & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVRA | ENOV |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2009 | 2008 |
| Metric | SVRA | ENOV |
|---|---|---|
| Price | $5.05 | $18.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $10.94 | ★ $38.33 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.08 |
| Revenue Next Year | $3,963.52 | $4.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $17.30 |
| 52 Week High | $7.01 | $34.28 |
| Indicator | SVRA | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 36.54 |
| Support Level | $5.16 | $17.30 |
| Resistance Level | $5.49 | $26.97 |
| Average True Range (ATR) | 0.22 | 0.85 |
| MACD | -0.01 | 0.25 |
| Stochastic Oscillator | 45.11 | 32.64 |
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.